Evidence map›Paper›PMID 28143897›Full record

ReviewJournal of the American Society of Nephrology : JASN2017

Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment.

Lennart Tonneijck, Marcel H A Muskiet, Mark M Smits, Erik J van Bommel, Hiddo J L Heerspink, Daniël H van Raalte, Jaap A Joles

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of the American Society of Nephrology : JASN, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 452 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
452citing papers in PubMed, 10 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

452 citing papers in PubMed, 10 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Guideline
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Article
  17. Observational
  18. Observational
  19. Article
  20. Article

392 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lennart TonneijckDiabetes Center, Department of Internal Medicine, VU University Medical Center, Amsterdam, The Netherlands; l.tonneijck@vumc.nl.
Marcel H A MuskietDiabetes Center, Department of Internal Medicine, VU University Medical Center, Amsterdam, The Netherlands.
Mark M SmitsDiabetes Center, Department of Internal Medicine, VU University Medical Center, Amsterdam, The Netherlands.
Erik J van BommelDiabetes Center, Department of Internal Medicine, VU University Medical Center, Amsterdam, The Netherlands.
Hiddo J L HeerspinkDepartment of Clinical Pharmacology, University Medical Center Groningen, Groningen, The Netherlands; and.
Daniël H van RaalteDiabetes Center, Department of Internal Medicine, VU University Medical Center, Amsterdam, The Netherlands.
Jaap A JolesDepartment of Nephrology and Hypertension, University Medical Center, Utrecht, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An absolute, supraphysiologic elevation in GFR is observed early in the natural history in 10%-67% and 6%-73% of patients with type 1 and type 2 diabetes, respectively. Moreover, at the single-nephron level, diabetes-related renal hemodynamic alterations-as an adaptation to reduction in functional nephron mass and/or in response to prevailing metabolic and (neuro)hormonal stimuli-increase glomerular hydraulic pressure and transcapillary convective flux of ultrafiltrate and macromolecules. This phenomenon, known as glomerular hyperfiltration, classically has been hypothesized to predispose to irreversible nephron damage, thereby contributing to initiation and progression of kidney disease in diabetes. However, dedicated studies with appropriate diagnostic measures and clinically relevant end points are warranted to confirm this assumption. In this review, we summarize the hitherto proposed mechanisms involved in diabetic hyperfiltration, focusing on ultrastructural, vascular, and tubular factors. Furthermore, we review available evidence on the clinical significance of hyperfiltration in diabetes and discuss currently available and emerging interventions that may attenuate this renal hemodynamic abnormality. The revived interest in glomerular hyperfiltration as a prognostic and pathophysiologic factor in diabetes may lead to improved and timely detection of (progressive) kidney disease, and could provide new therapeutic opportunities in alleviating the renal burden in this population.

Indexed as

Glomerular Filtration RateDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2HumansKidney Glomerulusalbuminuriadiabetesdiabetic nephropathyglomerular filtration rateglomerular hyperfiltration

Identifiers

PMID28143897
PMCPMC5373460

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.